Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | SVP, Clinical Development | October 23, 2017 | October 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date October 23, 2017 · Filed October 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2027-10-22 | Direct | 11,000 |
Reported balance
After 2017-10-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-23 · Grant · Acquired 11,000 · Balance 11,000 F1: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 23, 2017 Filed Oct 24, 2017 22:45 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006255 · formfour.xml · derivative · entry 1 GOLDBERG Y. PAUL · CIK 0001619960 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 20:25 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001505 · formfour.xml · derivative · entry 1 GOLDBERG Y. PAUL · CIK 0001619960 · SVP, Clinical Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Shares · 27,500 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.